Tag : hemophilia

Latest News

Global Hemophilia Treatment Drugs Market Drivers, Restraints & Opportunities During the Forecast Period, 2018-2026 – ResearchAndMarkets.com

Newsemia
DUBLIN–(BUSINESS WIRE)–The “Hemophilia Treatment Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026” report has been added to ResearchAndMarkets.com’s offering. Hemophilia...
Pharma / Biotech

Pharmacokinetics, immunogenicity, safety and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1).

Newsemia
Related Articles Pharmacokinetics, immunogenicity, safety and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1). J Thromb...
Latest News

Genentech Presents a Broad Range of Data for Hemlibra (Emicizumab-kxwh) Demonstrating Continued Benefits for People With Hemophilia A at the ISTH 2019 Congress

Newsemia
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data for Hemlibra® (emicizumab-kxwh) across multiple...
Latest News

Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels

Newsemia
BRISBANE, Calif. & NEW YORK–(BUSINESS WIRE)–Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, and Pfizer, Inc. (NYSE: PFE) today announced updated results from the...
Pediatrics

Gene-Based Factor VIIa Prevents Bleeding Episodes in Animals with Hemophilia

Newsemia
Hematology researchers have further refined how a treatment currently used urgently to control bleeding in hemophilia patients holds promise for prevention as well. A study...
Latest News

Takeda Announces Results from First-of-Its-Kind Phase IIIb/IV Trial PROPEL – a Randomized PK-Guided Prophylaxis Study Evaluating Higher Factor VIII Levels in Hemophilia A– at EAHAD 2019

Newsemia
CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”), the global biotechnology leader in rare diseases, has today announced results from its phase...
Latest News

Chugai’s Hemlibra® Gains Positive CHMP Opinion in Severe Hemophilia A Without Inhibitors

Newsemia
TOKYO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/antibodydrug?src=hash" target="_blank"gt;#antibodydruglt;/agt;–Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Roche has received notification that the EU Committee for Medicinal Products for Human Use...
Pharma / Biotech

The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A.

Newsemia
Related Articles The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A. Thromb Res. 2018 Aug...
Cardiology

Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report.

Newsemia
Related ArticlesPregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. Am J Gastroenterol. 2018 Jul 19;: Authors: Lichtenstein GR, Feagan BG, Mahadevan U,...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy